Comparison of Inhaled Ciclesonide (160 Mcg b.i.d. or 320 Mcg b.i.d.) and Fluticasone Propionate (250 Mcg b.i.d. or 500 Mcg b.i.d.) in Pretreated Patients With Mild to Moderate Asthma

Trial Profile

Comparison of Inhaled Ciclesonide (160 Mcg b.i.d. or 320 Mcg b.i.d.) and Fluticasone Propionate (250 Mcg b.i.d. or 500 Mcg b.i.d.) in Pretreated Patients With Mild to Moderate Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
  • Sponsors ALTANA Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 May 2012 Company added to the associations field as reported by ClinicalTrials.gov record.
    • 11 Feb 2010 Pharmacokinetic results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top